JAKAFI
ruxolitinibsmall moleculeJAK1/JAK2 inhibitor
Myelofibrosis
Approved
1 program·1 trial·View drug →
DashboardSell21,225$70.21−$1.5MAward7,658$96.99$742.8KSell24,095$85.67−$2.1MSell4,079$101.98−$416.0K Radiation OncologyCo-Investigator$833.7K7Surgical OncologyResearch Grant$779.3K5Medical OncologyCo-Investigator$615.0K7Medical OncologyCo-Investigator$587.3K6Medical OncologyCo-Investigator$573.2K7Surgical OncologyCo-Investigator$539.0K4Medical OncologyResearch Grant$511.4K4Surgical OncologyCo-Investigator$372.2K6Surgical OncologyCo-Investigator$325.1K5Surgical OncologyEquity / Ownership$296.2K6
INCYNASDAQ
Incyte
Incyte Corporation · Wilmington, DE · founded 1991
Incyte is a Wilmington, Delaware biopharma focused on small-molecule inhibitors of disease-driving kinases. Lead product JAKAFI (ruxolitinib) treats myelofibrosis, polycythemia vera, and graft-versus-host disease by blocking JAK1/2 enzymes, while topical OPZELURA is approved for vitiligo and atopic dermatitis. The pipeline targets additional hematology, oncology, and immunology indications.
- Lead asset
- JAKAFI · Approved · Myelofibrosis
- small molecule · JAK1/JAK2 inhibitor
- Pipeline
- 1 drug · 1 program
- 1 Oncology - Heme
- Modalities
- small molecule×1
FocusOncology - HemeImmunologyOncology - Solid
$78.00+9.84%1Y
INCY · daily close · illustrative · 2 catalysts marked
PDUFA+29%Interim-9%
1Y high$78.561Y low$69.26range$9.30(13%)past catalysts
Peers in this space
CRSP$4.4B
CRISPR Therapeutics
Rel.
0.37
Oncology - Hemecell therapy
1 programmatch: sector
BEAM$2.1B
Beam Therapeutics
Rel.
0.30
Oncology - Hemecell therapy
1 programmatch: sector
EDIT$380M
Editas Medicine
Rel.
0.28
Oncology - Hemecell therapy
1 programmatch: sector
CRBU$240M
Caribou Biosciences
Rel.
0.24
Oncology - Hemecell therapy
1 programmatch: sector
BMY$105.0B
Bristol Myers Squibb
Rel.
0.65
Cardiology - HFpEFsmall molecule
1 programmatch: modality
MDGL$6.8B
Madrigal
Rel.
0.57
NASH / MASHsmall molecule
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Nov 26, 2025PDUFAJAKAFI — PDUFA — ApprovedPositive+29.3%+44.7%+30.7%
Jul 29, 2025InterimJAKAFI — Phase 3 Interim — Stopped for EfficacyNegative-8.7%-9.7%-12.2%
Mar 1, 2025InterimJAKAFI — Phase 3 Interim — Stopped for EfficacyPositive+12.0%+10.0%+15.1%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 4 transactions · 4 insiders
Net flow
−$4.0M
Buys
$0
0 txns
Sells
$4.0M
3 txns
Largest
−$2.1M
CMO sell
Net flow per quarter · last 8Q
4 txns · sum −$3.97M
24Q325Q125Q326Q126Q2
buys · $0sells · $3.97M
Insider · roleActionSharesPriceValueDate
A. Nguyen
CMO
Apr 25, 2026
S. Iyer
CFO
Apr 20, 2026
K. O'Connor
CMO
Apr 2, 2026
N. O'Connor
CMO
Mar 20, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
4 trades · 3 members
Est. net flow
+$1.54M
midpoint · brackets only
Buys
4
Sells
0
Party mix
3 D1 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Buy$15K–$50K~$33KspouseRep. L. Marquez
House · NM
Mar 10, 2026
filed +39d
D
Buy$500K–$1.00M~$750KspouseRep. K. Linville
House · WA
Feb 2, 2026
filed +4d
R
Buy$500K–$1.00M~$750KspouseRep. Q. Yates
House · AL
Oct 24, 2025
filed +9d
D
Buy$1K–$15K~$8KspouseRep. L. Marquez
House · NM
Oct 14, 2025
filed +39d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
3 ETFs hold the position
Held by ETFs
$116.9M
aggregate position
Of market cap
0.80%
aggregate ETF share
Top holder
XLV0.19%
Health Care Select Sector SPDR
TickerETF · familyThemeNAV% of NAVPosition
XLVBroad healthcare$39.00B0.19%$74.1M
Health Care Select Sector SPDR
SPDR
IBBBroad biotech$8.40B0.34%$28.6M
iShares Biotechnology ETF
iShares
XBIBroad biotech$7.90B0.18%$14.2M
SPDR S&P Biotech ETF
SPDR
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
24 physicians paid · 110 disclosed records
Total 2025+2024
$8.10M
YoY
+60%
Co-Investigator$4.07MResearch Grant$2.02MEquity / Ownership$1.41MSpeaking$290.2KConsulting$269.0KTravel & Lodging$43.5KFood & Beverage$3.5K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Devon Davies
Vanderbilt
Dr. Robert Nakamura
Penn Medicine
Dr. Kavya Lindberg
Yale Medical
Dr. Henry Hoffman
NYU Langone
Dr. Theo Andersson
MD Anderson
Dr. Henry Hoffman
Yale Medical
Dr. Olivia Park
Cedars-Sinai
Dr. James Greene
Memorial Sloan Kettering
Dr. Sarah Hoffman
Mass General Hospital
Dr. Vivian Reyes
University of Washington
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$1.09M disclosed · 4 firms engaged
YoY change
+12%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Tiber Creek Group$407K
5 quarters active
Cornerstone Government Affairs$308K
5 quarters active
Invariant$240K
5 quarters active
Forbes-Tate Partners$137K
3 quarters active
Top issues lobbied
- Prescription Drug User Fee programs$342K
- Inflation Reduction Act drug-price negotiation$136K
- Pharmacy Benefit Manager (PBM) reform$136K
- GLP-1 coverage under Medicare Part D$136K
- Sunshine Act expansion$103K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
2 awards · 2 agencies
Total awarded
$60.3M
across all programs
Active
$6.9M
option periods incl.
Top agency
NIH / NCI$53.4M
largest active: Veterans Health Administration — Specialty Drug Supply
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NCIcompleted$53.4MSep 2024→ Jan 2026
Immuno-Oncology Combination Trial Sponsorship
Cooperative Agreement · NIH-68522874
VAoption$6.9MJul 2023→ Feb 2027
Veterans Health Administration — Specialty Drug Supply
Contract · VA-63887554
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
5 granted · 4 pending
Total in portfolio
9
Granted in last 12mo
1
Expiring < 2yr
0
Nearest expiry
Apr 2031
Patent #Title · inventor · drugTypeStatus · filedExpiry
10,887,233Composition of Matter
Lipid nanoparticle formulations comprising JAKAFI
J. Walsh + 2 · JAKAFI
grantedfiled Apr 2026
exp. Apr 2046
20.0y left
US 2026/0427579 A1Process
Scalable cell-line manufacturing for JAKAFI
K. Patel + 2 · JAKAFI
pendingfiled Apr 2026
in prosecution
US 2024/8952361 A1Formulation
Stable lyophilized formulations of JAKAFI
K. Hoffman + 3 · JAKAFI
pendingfiled Apr 2024
in prosecution
12,105,258Formulation
Subcutaneous injectable formulations of JAKAFI
M. Reyes + 2 · JAKAFI
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
US 2022/0201216 A1Method of Use
Dosing regimens for chronic administration of JAKAFI
B. Romano · JAKAFI
pendingfiled Apr 2022
in prosecution
10,447,624Method of Use
Methods of treating advanced disease using JAKAFI
D. Romano + 1 · JAKAFI
grantedfiled Apr 2017
exp. Apr 2037
11.0y left
US 2020/3898560 A1Composition of Matter
Bispecific antibody compositions targeting JAKAFI
B. Kowalski + 2 · JAKAFI
pendingfiled Apr 2020
in prosecution
10,337,880Formulation
Subcutaneous injectable formulations of JAKAFI
D. Romano + 3 · JAKAFI
grantedfiled Apr 2016
exp. Apr 2036
10.0y left
showing 8 of 9 · full portfolio available on Pro
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
16 items from 3 categories
clinical11regulatory3partnership2
8d ago
FDA grants Fast Track Designation to INCY's JAKAFI program
Endpoints News$·regulatory
12d ago
INCY completes enrollment in JAKAFI Phase 2 trial
FierceBiotech·clinical
15d ago
INCY enters licensing agreement with major pharma for JAKAFI
PR Newswire·partnership
16d ago
INCY doses first patient in Phase 3 JAKAFI study
FierceBiotech·clinical
21d ago
FDA accepts INCY's NDA for JAKAFI; PDUFA date set
Endpoints News$·regulatory
23d ago
INCY reports topline results from Phase 2 trial of JAKAFI
Endpoints News$·clinical
24d ago
INCY announces strategic collaboration in rare disease
PR Newswire·partnership
27d ago
INCY completes enrollment in JAKAFI Phase 2 trial
PR Newswire·clinical
1mo ago
INCY reports topline results from Phase 2 trial of JAKAFI
PR Newswire·clinical
1mo ago
INCY presents JAKAFI data at major medical conference
FierceBiotech·clinical
1mo ago
INCY completes enrollment in JAKAFI Phase 2 trial
Endpoints News$·clinical
2mo ago
INCY announces interim analysis from JAKAFI pivotal study
FierceBiotech·clinical
2mo ago
INCY receives Orphan Drug Designation for JAKAFI
Endpoints News$·regulatory
2mo ago
INCY presents JAKAFI data at major medical conference
Endpoints News$·clinical
2mo ago
INCY presents JAKAFI data at major medical conference
FierceBiotech·clinical
3mo ago
INCY reports topline results from Phase 2 trial of JAKAFI
Endpoints News$·clinical
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$78.00
Open
$77.61
Day Δ
+0.39
+0.50%
Day range
$77.14 – $78.47
52W range
$69.26 – $78.56
Avg daily volume
1.57M
Valuation & ownership
Enterprise value
$13.4B
Shares out
187.18M
Float
172.21M
Insider %
3.67%
Institutional %
58.67%
Beta
1.67
vs SPY · 52w
Balance sheet & burn
Cash + invest
$2.3B
Total debt
$978M
Debt / equity
6.67
Cash burn / Q
$74M
R&D spend TTM
$311M
13% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.72
EPS Δ vs prior
+0.07
EPS estimate
$-0.75
next quarter
EPS prior
$-0.79
Next earnings
Jul 9, 2026
Rev guidance
$175M